Table 1.
Patients' Characteristics and the Treatment of Primary Thyroid Lymphoma
| Variables | Patients aged above 60 years Number (%) | Patients aged above 70 years Number (%) |
|---|---|---|
| No. of patients | 43 | 26 |
| Age (median [range]) (years) | 71 [60–86] | 75 [70–86] |
| Sex (male/female) | 14/29 (33/67) | 9/17 (35/65) |
| Hashimoto's disease | 37 (86) | 23 (88) |
| Pathologic diagnosis | ||
| DLBCL | 32 (74) | 22 (85) |
| DLBCL with MALT lymphoma | 11 (26) | 4 (15) |
| Laboratory tests at diagnosis | ||
| Elevated LDH | 16 (41) | 11 (48) |
| ESR (median [range]) (mm) | 26 [2–82] | 27 [3–75] |
| Free T3 (median [range]) (pg/mL) | 2.8 [2.3–3.5]a | 2.8 [2.3–3.3]a |
| Free T4 (median [range]) (ng/dL) | 1.1 [0.5–1.7]a | 1.1 [0.5–1.7]a |
| TSH (median [range]) (μIU/mL) | 4.2 [0.1–97]a | 5.4 [0.1–97]a |
| TSH (decreased/normal range/elevated) | 1/14/14 (3.4/48.3/48.3)a | 1/7/18 (4/27/69)a |
| sIL-2R (median [range]) (U/mL) | 639 [234–2850] | 716 [298–2850] |
| Clinical stage (IE/IIE) | 12/31 (28/ 72) | 7 19 (27/ 73) |
| Treatment | ||
| Chemotherapy (alone/with irradiation) | 4/39 (9/ 91) | 4/22 (15/ 85) |
| R-CHOP (1–3/4–6 courses) | 41/2 (95/5) | 25/1b (96/4) |
| Doses of irradiation (median [range]) (gray) | 36 [30–40] | 36 [30–40] |
| Dosage of R-CHOP therapy (median [range]) | ||
| R/BSA (mg/m2){%}c | 375 [273–392] {100 [73–104]} | 375 [273–392] {100 [73–105]} |
| CPA/BSA (mg/m2){%} | 750 [413–758] {100 [55–101]} | 736 [413–758] {98 [55–101]} |
| VCR/BSA (mg/m2){%} | 1.2 [0.6–1.4] {87 [45–100]} | 1.1 [0.6–1.4] {80 [45–100]} |
| ADM/BSA(mg/m2){%} | 40 [26–49] {79 [52–98]} | 39 [26–40] {79 [52–81]} |
| PSL/body (mg/body) | 100 [0–100] | 100 [0–100] |
a
Patients with thyroid hormone replacement therapy were excluded.
b
For one patient, after six courses of R-CHOP therapy and irradiation, rituximab was added four times monthly.
c
A percentage of the conventional dose.
DLBCL, diffuse large B-cell lymphoma; MALT, mucosa-associated lymphoid tissue; LDH, lactase dehydrogenase; ESR, erythrocyte sedimentation rate; T3, triiodothyronine; T4, thyroxine; TSH, thyrotropin; R, rituximab; CPA, cyclophosphamide; VCR, vincristine; ADM, adriamycin; PSL, prednisolone; BSA, body surface area.